Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Kidney and HSCT for Tolerance in ESRD
NCT02176434Phase 1Recruiting
- Sponsor
- University of Zurich
- Start
- Sep 2015
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hematopoietic stem cells in end stage renal disease (ESRD), sponsored by University of Zurich. Primary endpoint: Renal allograft acceptance and ability to discontinue immunosuppressive therapy at 1 year. Started Sep 2015; status: recruiting.
02
Drugs
hematopoietic stem cells
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT02176434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176434.